Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 54

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 54
---
 of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements. The guidance in ASU 2023-09 will be effective for annual reporting periods in fiscal years beginning after December 15, 2024. The Company discloses its income tax rate reconciliation in its annual financial statements only and does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements.In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as subsequently amended by ASU 2025-01 to clarify the effective date, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented in the statement of operations. The guidance in this ASU is effective for annual reporting periods in fiscal years beginning after December 15, 2026, and interim periods in fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its financial statement disclosures.

Note 4.    Cash and Cash Equivalents

Cash and cash equivalents consisted of the following (in thousands):June 30,2025December 31,2024Savings and checking accounts at major U.S. financial institutions$118 $428 U.S. Treasury securities money market fund2,098 2,162 Total$2,216 $2,590 

Note 5.    Prepaid Expenses and Other Current Assets

Prepaid expenses consisted of the following (in thousands):June 30,2025December 31,2024Prepaid insurance$282 $421 Prepaid research and development costs312 239 Prepaid other228 113 Total$822 $773 

7

Note 6.    Accrued Expenses

Accrued expenses consisted of the following (in thousands):June 30,2025December 31,2024Accrued